Seth Goldblum, James Schoeneck

BrainCells this week announced the addition of Seth Goldblum as vice president of business development. Goldblum is responsible for evaluating in-licensing and collaboration opportunities for compounds that promote neurogenesis for central nervous system indications. Goldblum reports to CEO James Schoeneck.
Prior to joining BCI, Goldblum was head of business development for Senomyx. Before that, he served in executive positions with Vical.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.